Skip to content

The effect of intranasal corticosteroids on chronic idiopathic urticaria

The effect of intranasal corticosteroids in adults with chronic idiopathic urticaria and positive prick test with aeroallergens

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231229060563N1
Enrollment
69
Registered
2024-05-04
Start date
2024-03-09
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic urticaria. Idiopathic urticaria

Interventions

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients must be older than eighteen years. Patients must have a diagnosis of idiopathic urticaria and positive prick test results for airborne antigens. Patients must choose from adult allergy clinics and declare their informed consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients who are under treatment other than antihistamines by a doctor specializing in asthma and allergies. Patients who cannot participate during six months. Patients who had serious side effects due to corticosteroids before the start of the study. Patients who have serious side effects caused by the use of corticosteroids during the study period.

Design outcomes

Primary

MeasureTime frame
Primary outcome measures include the frequency and severity of urticaria symptoms, which are evaluated using valid scoring systems such as the Urticaria Activity Score and the Urticaria Severity Score. Timepoint: At the beginning of the study (before the start of the intervention) and six months after the start of corticosteroid use. Method of measurement: Urticaria severity and activity questionnaire.

Secondary

MeasureTime frame
Secondary outcome measures will include the impact of urticaria on quality of life and daily activities, which will be evaluated using age-appropriate validation questionnaires. Timepoint: At the beginning of the study (before the start of the intervention) and six months later. Method of measurement: Questionnaire of the effect of urticaria on the quality of life.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Mohtadi

Shiraz University of Medical Sciences

Hasanmohtadi@sums.ac.ir+98 71 3636 5895

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026